Etiology and Triggers in the Development of Fibromyalgia

Amsterdam, Dana; Buskila, Dan

doi:10.1007/978-3-030-78638-0_3

Cited by 1 publication

(1 citation statement)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The widespread pain experienced by individuals with fibromyalgia has been attributed to primarily central mechanisms such as central sensitization at the spinal level and abnormal pain processing in the brain (Desmeules et al, 2003;Cagnie et al, 2014). Although the exact cause of fibromyalgia is not fully understood, biological factors, mechanical/physical trauma or injury, genetic factors, and psychosocial stressors have been held responsible for the painful condition (Sommer et al, 2008;Amsterdam and Buskila, 2021). The disease is well known for the abnormal pain sensitivity that it causes, along with abnormal neurotransmitter levels in cerebrospinal fluid (CSF), abnormal activation of cerebral pain-processing areas, and abnormal peripheral pain and sensory thresholds (Larson et al, 2000;Staud and Domingo, 2001;Staud, 2002).…”

Section: Introductionmentioning

confidence: 99%

Pharmacological treatments of fibromyalgia in adults; overview of phase IV clinical trials

Alorfi

2022

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Fibromyalgia is a chronic neurological condition characterized by widespread pain. The effectiveness of current pharmacological treatments is limited. However, several medications have been approved for phase IV trials in order to evaluate them.Aim: To identify and provide details of drugs that have been tested in completed phase IV clinical trials for fibromyalgia management in adults, including the primary endpoints and treatment outcomes. This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology.Method: Publicly available and relevant phase IV trials registered at ClinicalTrials.gov were analyzed. The uses of the trialed drugs for fibromyalgia were reviewed.Results: As of 8 August 2022, a total of 1,263 phase IV clinical trials were identified, of which 121 were related to fibromyalgia. From these, 10 clinical trials met the inclusion criteria for the current study. The drugs used in phase IV trials are milnacipran, duloxetine, pregabalin, a combination of tramadol and acetaminophen, and armodafinil. The effectiveness of the current pharmacological treatments is apparently limited.Conclusion: Due to its complexity and association with other functional pain syndromes, treatment options for fibromyalgia only are limited and they are designed to alleviate the symptoms rather than to alter the pathological pathway of the condition itself. Pain management specialists have numerous pharmacologic options available for the management of fibromyalgia.

show abstract

Section: Introductionmentioning

confidence: 99%

Pharmacological treatments of fibromyalgia in adults; overview of phase IV clinical trials

Alorfi

2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

Etiology and Triggers in the Development of Fibromyalgia

Cited by 1 publication

References 63 publications

Pharmacological treatments of fibromyalgia in adults; overview of phase IV clinical trials

Pharmacological treatments of fibromyalgia in adults; overview of phase IV clinical trials

Contact Info

Product

Resources

About